Is OPKO Health a Diagnostics Stock Worth Buying?

NASDAQ: OPK | OPKO Health Inc. News, Ratings, and Charts

OPK – Multinational biopharmaceutical company OPKO Health’s (OPK) stock climbed nearly 13% in price last year when the company announced its plans to acquire ModeX Therapeutics. However, given the company’s declining financials and negative profit margins, is it worth buying the stock now? Let’s discuss.

OPKO Health Inc. (OPK) in Miami, Fla., is a global biopharmaceutical and diagnostics company that aims to achieve industry-leading positions in large, rapidly expanding industries by maximizing its experience in discovery, development, and commercialization, and its unique and patented technology. In May, the company acquired ModeX Therapeutics, Inc., and by doing so obtained exclusive immunotherapy technologies. Also, during the reported quarter, Pfizer Inc. (PFE) released OPKO Health’s NGENLA injectable in Germany, Japan, Canada, and Australia, and is on track to make it accessible in the United States.

However, the company’s shares are down 23.6% in price over the past year and 42.6% year-to-date to close yesterday’s trading session at $2.76.

OPK’s year-over-year decline in its top line and its sustained loss per share are causes for concern. In addition, decreasing diagnostics revenues due to lower BRL testing numbers and a fall in RAYALDEE sales are also concerning.

Here is what could shape OPK’s performance in the near term:

Inadequate Financials

OPK’s total revenue declined 39.6% year-over-year to $329.2 million for the first quarter ended March 31, 2022. Its operating loss came in at $72.4 million compared to  $28.5 million in operating income  in the prior-year quarter. The company reported a net loss of $55.4 million compared to $31.1 million in net income in the first quarter of 2021. Its loss per share amounted to $0.08. In addition, its cash and cash equivalents declined 24.1% for the three months ended March 31, 2022, to $102.3 million.

Poor Profitability

OPK’s 1.81% trailing-12-month CAPEX/Sales  is 58.1% lower than the 4.31% industry average. Its 26.3% trailing-12-month gross profit margin is 52.8% lower than the 55.6% industry average. Also, its trailing-12-month ROA, ROC, and net income margin are negative 5.1%, 3.8%, and 7.5%, respectively.

POWR Ratings Reflect Bleak Outlook

OPK has an overall D rating, which equates to Sell in our proprietary POWR Ratings system. The POWR ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. OPK has a C for Stability and Quality. The stock 1.89 beta is in sync with the Stability grade. In addition, the company’s poor profitability is consistent with the Quality grade.

Of the 52 stocks in the D-rated Medical – Diagnostic/Research industry, OPK is ranked #38.

Beyond what I have stated above, you can view OPK ratings for Growth, Value, Momentum, and Sentiment here.

Click here to checkout our Semiconductor Industry Report for 2022

Bottom Line

OPK’s deteriorating financial performance and negative profit margins are concerning. In addition, analysts expect its EPS to decline 300% in the next quarter (ending June 2022) and 380% in the current year. Furthermore, the stock is currently trading below its 50-day and 200-day moving averages of $3.10 and $3.62, respectively, indicating a downtrend. So, we think the stock is best avoided now.

How Does OPKO Health Inc. (OPK) Stack Up Against its Peers?

While OPK has an overall D rating, one might want to consider its industry peers, Global Cord Blood Corporation (CO), Qiagen N.V. (QGEN), and Agilent Technologies Inc. (A), which have an overall A (Strong Buy) rating.


OPK shares rose $0.01 (+0.36%) in premarket trading Tuesday. Year-to-date, OPK has declined -42.62%, versus a -13.03% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
OPKGet RatingGet RatingGet Rating
COGet RatingGet RatingGet Rating
QGENGet RatingGet RatingGet Rating
AGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Bulls in Charge…for Now at Least

Every since the S&P 500 (SPY) made new lows in mid June the bulls have been back in charge. At first it looked like your typical bear market rally. However, there are more and more signals going off that this may be the real deal. As in the new bull market may have arrived. That topic is a big deal as one's outlook, bullish or bearish, weighs heavily on how they construct their portfolio for the days and weeks ahead. That is why we will focus on that topic in today's commentary. Read on below for more…

:  |  News, Ratings, and Charts

The 3 Top Aerospace and Defense Stocks to Buy Now

The U.S. aerospace and defense industry is evolving, supported by lucrative fiscal investments and rapid defense technology advancement. Moreover, given the growing tension between China and Taiwan, it could be wise to add quality aerospace and defense stocks, Lockheed Martin (LMT), L3Harris Technologies (LHX), and Raytheon Technologies Corp. (RTX) to your portfolio now. Continue reading…

:  |  News, Ratings, and Charts

How to RIDE the Next Bull Market?

Growth stocks are back! And, they are leading the S&P 500 (SPY) higher after the brutal bear market investors experienced this year. Read on to find out the best strategy to profit from the next big bull market in growth stocks...

:  |  News, Ratings, and Charts

2 Momentum Stocks Crushing the Bear Market

Valero Energy (VLO) and Shell (SHEL) have maintained strong momentum amid the highly uncertain market conditions. With recession fears expected to keep the market under pressure in the near term, it could be wise to buy these stocks now to benefit from their momentum, which might continue for some time based on their fundamental strength irrespective of the market conditions. Read on…

:  |  News, Ratings, and Charts

How to RIDE the Next Bull Market?

Growth stocks are back! And, they are leading the S&P 500 (SPY) higher after the brutal bear market investors experienced this year. Read on to find out the best strategy to profit from the next big bull market in growth stocks...

Read More Stories

More OPKO Health Inc. (OPK) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All OPK News